Exegenesis Bio, a Philadelphia gene therapy company, raised over $10 million in initial funding from China investors, K2VC, Kaitai Capital and Lenovo Star. The company is developing affordable first-in-class and best-in-class gene therapies for high unmet needs, which it will market in China and globally. The company’s executive team averages 15 years experience in cell and gene therapy in US companies. Zhenhua Wu, PhD, founder and CEO of Exegenesis, previously worked at several innovative biopharmas in the Philadelphia area and also at GSK and Merck.
Source: China Biotoday
